[
  {
    "ts": null,
    "headline": "Eli Lilly Preps Oral Weight-Loss Launch",
    "summary": "Inventory ramps ahead of approval",
    "url": "https://finnhub.io/api/news?id=dbf8ede4fdf17cecec13f275cdd6647323213b8d33a771bc23b8ca5725ac019d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771366329,
      "headline": "Eli Lilly Preps Oral Weight-Loss Launch",
      "id": 139127286,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Inventory ramps ahead of approval",
      "url": "https://finnhub.io/api/news?id=dbf8ede4fdf17cecec13f275cdd6647323213b8d33a771bc23b8ca5725ac019d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Reports Phase 3 Win for Retevmo in Early Lung Cancer",
    "summary": "LIBRETTO-432 shows statistically significant event-free survival benefit in RET fusion-positive NSCLC after initial therapy.",
    "url": "https://finnhub.io/api/news?id=2218f5b65fcbbff66bbaa225571f0134f4e5bfbe0786efb8637f8f5baef9733c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771365614,
      "headline": "Eli Lilly Reports Phase 3 Win for Retevmo in Early Lung Cancer",
      "id": 139127287,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LIBRETTO-432 shows statistically significant event-free survival benefit in RET fusion-positive NSCLC after initial therapy.",
      "url": "https://finnhub.io/api/news?id=2218f5b65fcbbff66bbaa225571f0134f4e5bfbe0786efb8637f8f5baef9733c"
    }
  },
  {
    "ts": null,
    "headline": "Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash",
    "summary": "Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.",
    "url": "https://finnhub.io/api/news?id=615cef3d832484c7a8b39e1b09821064e76f4445bc322dd0085747c9eb7ddf5e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771361902,
      "headline": "Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash",
      "id": 139126530,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.",
      "url": "https://finnhub.io/api/news?id=615cef3d832484c7a8b39e1b09821064e76f4445bc322dd0085747c9eb7ddf5e"
    }
  },
  {
    "ts": null,
    "headline": "Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million",
    "summary": "This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.",
    "url": "https://finnhub.io/api/news?id=918fdb1d9e6750a372c232e7e193dac09c2cf97a799dcebc998844949ea57901",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771361280,
      "headline": "Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million",
      "id": 139126531,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.",
      "url": "https://finnhub.io/api/news?id=918fdb1d9e6750a372c232e7e193dac09c2cf97a799dcebc998844949ea57901"
    }
  },
  {
    "ts": null,
    "headline": "Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake",
    "summary": "Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.",
    "url": "https://finnhub.io/api/news?id=bb705137de912d55e00a9ca44f85c25dd4e95dd0717dfa7eaaf2da50ad8cca27",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771360950,
      "headline": "Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake",
      "id": 139126532,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.",
      "url": "https://finnhub.io/api/news?id=bb705137de912d55e00a9ca44f85c25dd4e95dd0717dfa7eaaf2da50ad8cca27"
    }
  },
  {
    "ts": null,
    "headline": "Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More",
    "summary": "Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.",
    "url": "https://finnhub.io/api/news?id=1b287e9783111721d17fd3cd1f9dd12ce13d900f80b09644741eddc561525962",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771360600,
      "headline": "Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More",
      "id": 139126533,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.",
      "url": "https://finnhub.io/api/news?id=1b287e9783111721d17fd3cd1f9dd12ce13d900f80b09644741eddc561525962"
    }
  },
  {
    "ts": null,
    "headline": "1 Reason I'd Buy Eli Lilly Stock and Never Sell",
    "summary": "A robust pipeline is essential for a buy-and-hold pharmaceutical stock.",
    "url": "https://finnhub.io/api/news?id=eb656380afa38ebd259693e299783660d4e5fb6bfa0a1993899f3e5dd014a9f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771349700,
      "headline": "1 Reason I'd Buy Eli Lilly Stock and Never Sell",
      "id": 139125023,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A robust pipeline is essential for a buy-and-hold pharmaceutical stock.",
      "url": "https://finnhub.io/api/news?id=eb656380afa38ebd259693e299783660d4e5fb6bfa0a1993899f3e5dd014a9f3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Advances Gene Editing And Lung Cancer Programs With Valuation Upside",
    "summary": "Eli Lilly (NYSE:LLY) reached a second milestone in its CRISPR gene editing collaboration with Scribe Therapeutics, advancing programs in neurological and neuromuscular diseases. The company reported positive topline Phase 3 LIBRETTO-432 results for Retevmo in RET fusion positive early-stage non small cell lung cancer. Both updates point to progress in genetic medicines and targeted oncology for patients with high medical need. Eli Lilly sits at the intersection of large scale...",
    "url": "https://finnhub.io/api/news?id=a60ad4cf39f03c64dc695816bacf000f71ac80db755c99e89cbeeb0d85620c57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771344572,
      "headline": "Eli Lilly Advances Gene Editing And Lung Cancer Programs With Valuation Upside",
      "id": 139125024,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) reached a second milestone in its CRISPR gene editing collaboration with Scribe Therapeutics, advancing programs in neurological and neuromuscular diseases. The company reported positive topline Phase 3 LIBRETTO-432 results for Retevmo in RET fusion positive early-stage non small cell lung cancer. Both updates point to progress in genetic medicines and targeted oncology for patients with high medical need. Eli Lilly sits at the intersection of large scale...",
      "url": "https://finnhub.io/api/news?id=a60ad4cf39f03c64dc695816bacf000f71ac80db755c99e89cbeeb0d85620c57"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk",
    "summary": "Hims stock landed in hot water this month after Novo Nordisk slammed the telehealth giant with a lawsuit over its knockoff obesity drug.",
    "url": "https://finnhub.io/api/news?id=516d3c6544ca759a82dd41b3655cb1280e221287e96e13424c05bef6ad98b03a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771344276,
      "headline": "Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk",
      "id": 139124350,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims stock landed in hot water this month after Novo Nordisk slammed the telehealth giant with a lawsuit over its knockoff obesity drug.",
      "url": "https://finnhub.io/api/news?id=516d3c6544ca759a82dd41b3655cb1280e221287e96e13424c05bef6ad98b03a"
    }
  },
  {
    "ts": null,
    "headline": "ETY: This Option-Income Fund Could Be Riskier Than Commonly Believed",
    "summary": "ETY: This Option-Income Fund Could Be Riskier Than Commonly Believed",
    "url": "https://finnhub.io/api/news?id=972ef09681ec9dfc378d7bfa2f1cbc38d2e0117c3d154a19be64292c32c2a038",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771341901,
      "headline": "ETY: This Option-Income Fund Could Be Riskier Than Commonly Believed",
      "id": 139126193,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=972ef09681ec9dfc378d7bfa2f1cbc38d2e0117c3d154a19be64292c32c2a038"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Rises as $1.5 Billion Weight-Loss Pill Prepares to Hit Market",
    "summary": "LLY Prepares Big Launch for Oral Orforglipron. Competes With Novo Nordisk's Wegovy in Weight-Loss Market.",
    "url": "https://finnhub.io/api/news?id=4759c158c05723cf754bf4a452f09c3c3cf4138edf9dbf7df07b4c43730b4e63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771336755,
      "headline": "Eli Lilly Stock Rises as $1.5 Billion Weight-Loss Pill Prepares to Hit Market",
      "id": 139123919,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY Prepares Big Launch for Oral Orforglipron. Competes With Novo Nordisk's Wegovy in Weight-Loss Market.",
      "url": "https://finnhub.io/api/news?id=4759c158c05723cf754bf4a452f09c3c3cf4138edf9dbf7df07b4c43730b4e63"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Down Since Q4 Earnings Report: How to Play the Stock",
    "summary": "ABBV stock declines since it announced earnings results on Feb. 4. Skyrizi and Rinvoq fuel growth, offsetting Humira erosion.",
    "url": "https://finnhub.io/api/news?id=92bd175d0f32a0e0fb04227bca20e9dc19a05be6e178f06dcce127e222d25874",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771336620,
      "headline": "AbbVie Down Since Q4 Earnings Report: How to Play the Stock",
      "id": 139123920,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ABBV stock declines since it announced earnings results on Feb. 4. Skyrizi and Rinvoq fuel growth, offsetting Humira erosion.",
      "url": "https://finnhub.io/api/news?id=92bd175d0f32a0e0fb04227bca20e9dc19a05be6e178f06dcce127e222d25874"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Targets India as Global Export Hub Amid Surging Mounjaro Sales",
    "summary": "Company plans to scale $1 billion investment as weight-loss demand accelerates.",
    "url": "https://finnhub.io/api/news?id=94d94fcb500974ca6ea05b5444442c9e51fcbd1db2f4cd58da63777c378117e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771335431,
      "headline": "Eli Lilly Targets India as Global Export Hub Amid Surging Mounjaro Sales",
      "id": 139123921,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Company plans to scale $1 billion investment as weight-loss demand accelerates.",
      "url": "https://finnhub.io/api/news?id=94d94fcb500974ca6ea05b5444442c9e51fcbd1db2f4cd58da63777c378117e2"
    }
  },
  {
    "ts": null,
    "headline": "Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company",
    "summary": "ALAMEDA, Calif., February 17, 2026--Scribe Therapeutics achieves second success milestone for in vivo program in collaboration with Eli Lilly and Company",
    "url": "https://finnhub.io/api/news?id=cf8ea523f7f0bb4e0a1c143e4a752140135281f538aa707887f6f91ec578d219",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771333200,
      "headline": "Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company",
      "id": 139122086,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ALAMEDA, Calif., February 17, 2026--Scribe Therapeutics achieves second success milestone for in vivo program in collaboration with Eli Lilly and Company",
      "url": "https://finnhub.io/api/news?id=cf8ea523f7f0bb4e0a1c143e4a752140135281f538aa707887f6f91ec578d219"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: The Possible Upside",
    "summary": "Novo Nordisk stock experienced a sharp decline after disappointing 2025 results and 2026 outlook but has seen a bounce back since. Click to read my NVO update.",
    "url": "https://finnhub.io/api/news?id=9f58ece61252136e2e7fba817bb74c224885ceceaf70d6fe1f6ad40dd3e5be7f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771331818,
      "headline": "Novo Nordisk: The Possible Upside",
      "id": 139124914,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305436/image_2158305436.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk stock experienced a sharp decline after disappointing 2025 results and 2026 outlook but has seen a bounce back since. Click to read my NVO update.",
      "url": "https://finnhub.io/api/news?id=9f58ece61252136e2e7fba817bb74c224885ceceaf70d6fe1f6ad40dd3e5be7f"
    }
  },
  {
    "ts": null,
    "headline": "Reported Earlier\" 'Lilly targets India as global export hub amid booming Mounjaro sales, executive says' - Reuters",
    "summary": "https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-targets-india-global-export-hub-amid-booming-mounjaro-sales-executive-says-2026-02-17/",
    "url": "https://finnhub.io/api/news?id=9a8250af0b188aeca7ddcd4f267c53ec913515d3ea5f407bf17c2e636ed7ea13",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771324355,
      "headline": "Reported Earlier\" 'Lilly targets India as global export hub amid booming Mounjaro sales, executive says' - Reuters",
      "id": 139123612,
      "image": "",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-targets-india-global-export-hub-amid-booming-mounjaro-sales-executive-says-2026-02-17/",
      "url": "https://finnhub.io/api/news?id=9a8250af0b188aeca7ddcd4f267c53ec913515d3ea5f407bf17c2e636ed7ea13"
    }
  },
  {
    "ts": null,
    "headline": "Lilly targets India as global export hub amid booming Mounjaro sales, executive says",
    "summary": "HYDERABAD, Feb 17 (Reuters) - Mounjaro-maker Eli Lilly wants to turn India into a hub for its global supply chain, a senior executive ‌at the U. drugmaker said, as part of its previously committed $1 billion investment to ‌contract manufacturing in the country.",
    "url": "https://finnhub.io/api/news?id=82b12aba0e3a585f1cc831e2cd31252062bae6e2460f5c14e64a23e37b2647d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771322038,
      "headline": "Lilly targets India as global export hub amid booming Mounjaro sales, executive says",
      "id": 139120615,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "HYDERABAD, Feb 17 (Reuters) - Mounjaro-maker Eli Lilly wants to turn India into a hub for its global supply chain, a senior executive ‌at the U. drugmaker said, as part of its previously committed $1 billion investment to ‌contract manufacturing in the country.",
      "url": "https://finnhub.io/api/news?id=82b12aba0e3a585f1cc831e2cd31252062bae6e2460f5c14e64a23e37b2647d8"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co (NYSE:LLY) Combines Explosive Growth with a Bullish Technical Setup",
    "summary": "Eli Lilly (LLY) combines explosive earnings growth with a promising technical setup, offering a potential entry point for growth-focused investors.",
    "url": "https://finnhub.io/api/news?id=26c05b079be2fec1debefce5a2f46ecbde5d5b22608e5bd7a281bb0cfd4246a1",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771318862,
      "headline": "Eli Lilly & Co (NYSE:LLY) Combines Explosive Growth with a Bullish Technical Setup",
      "id": 139120439,
      "image": "https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp",
      "related": "LLY",
      "source": "ChartMill",
      "summary": "Eli Lilly (LLY) combines explosive earnings growth with a promising technical setup, offering a potential entry point for growth-focused investors.",
      "url": "https://finnhub.io/api/news?id=26c05b079be2fec1debefce5a2f46ecbde5d5b22608e5bd7a281bb0cfd4246a1"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients",
    "summary": "Eli Lilly&#39;s lung cancer trial shows lower recurrence risk and strong survival benefit in early-stage patients.",
    "url": "https://finnhub.io/api/news?id=69047792fc354dd9e56e1d370e66627ebbef24c62019ff94105819120ab30134",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771314124,
      "headline": "Eli Lilly's Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients",
      "id": 139122801,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/17/Eli-Lilly.jpeg?width=2048&height=1536",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "Eli Lilly&#39;s lung cancer trial shows lower recurrence risk and strong survival benefit in early-stage patients.",
      "url": "https://finnhub.io/api/news?id=69047792fc354dd9e56e1d370e66627ebbef24c62019ff94105819120ab30134"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Valuation Check After Positive Phase 3 Retevmo Results And GLP 1 Growth Momentum",
    "summary": "Eli Lilly (LLY) is back in focus after reporting statistically significant Phase 3 results for Retevmo in early stage RET fusion positive lung cancer, adding another clinical milestone to an already closely watched story. See our latest analysis for Eli Lilly. Against a backdrop of strong GLP 1 obesity and diabetes demand, upbeat 2026 revenue guidance and ongoing buybacks, Eli Lilly’s 1 year total shareholder return of 24.1% and very large 5 year total shareholder return of about 4.4x suggest...",
    "url": "https://finnhub.io/api/news?id=973086d31a83a3c8363d8d778d512f9de100fcdd057dc28fd28ab4ddc20bc292",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771304774,
      "headline": "Eli Lilly (LLY) Valuation Check After Positive Phase 3 Retevmo Results And GLP 1 Growth Momentum",
      "id": 139119712,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) is back in focus after reporting statistically significant Phase 3 results for Retevmo in early stage RET fusion positive lung cancer, adding another clinical milestone to an already closely watched story. See our latest analysis for Eli Lilly. Against a backdrop of strong GLP 1 obesity and diabetes demand, upbeat 2026 revenue guidance and ongoing buybacks, Eli Lilly’s 1 year total shareholder return of 24.1% and very large 5 year total shareholder return of about 4.4x suggest...",
      "url": "https://finnhub.io/api/news?id=973086d31a83a3c8363d8d778d512f9de100fcdd057dc28fd28ab4ddc20bc292"
    }
  },
  {
    "ts": null,
    "headline": "Reported Monday, Lilly Reports Retevmo Event-Free Survival Advantage In First Randomized Phase 3 Trial Of Selective RET Kinase Inhibitor In Early-Stage RET Fusion-Positive NSCLC",
    "summary": "Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or deathResults from the LIBRETTO-432 trial build on previous results",
    "url": "https://finnhub.io/api/news?id=fbb1f90b16a1ee0eb2572a434ac9db63bfa80959db78741f2bc4f5ad0c68b27b",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771303231,
      "headline": "Reported Monday, Lilly Reports Retevmo Event-Free Survival Advantage In First Randomized Phase 3 Trial Of Selective RET Kinase Inhibitor In Early-Stage RET Fusion-Positive NSCLC",
      "id": 139123614,
      "image": "",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or deathResults from the LIBRETTO-432 trial build on previous results",
      "url": "https://finnhub.io/api/news?id=fbb1f90b16a1ee0eb2572a434ac9db63bfa80959db78741f2bc4f5ad0c68b27b"
    }
  },
  {
    "ts": null,
    "headline": "Reported Monday, Eli Lilly Joins USOPC As Presenting Partner Of Team USA Athlete Recovery Program Building On Official Partner In Health Equity Role Through LA28 Olympic Games",
    "summary": "Reported Monday, Eli Lilly Joins USOPC As Presenting Partner Of Team USA Athlete Recovery Program Building On Official Partner In Health Equity Role Through LA28 Olympic Games",
    "url": "https://finnhub.io/api/news?id=213661506fccd643c35d0f25037604d8f24c72ce63b0756772dc477cc98da8d9",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771302142,
      "headline": "Reported Monday, Eli Lilly Joins USOPC As Presenting Partner Of Team USA Athlete Recovery Program Building On Official Partner In Health Equity Role Through LA28 Olympic Games",
      "id": 139123615,
      "image": "",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=213661506fccd643c35d0f25037604d8f24c72ce63b0756772dc477cc98da8d9"
    }
  }
]